Researchers at King’s College Hospital, led by Professor Christopher Shaw, have embarked on the first gene therapy clinical trial for ALS patients with a C9orf72 gene mutation. Since the mutated gene produces toxic products, blocking the gene with gene therapy might be a useful approach to treatment. Click here to read the full article
